Melina Cimler is the CEO and Founder of PandiaDx LLC and an Expert Consultant with NDA Partners, a ProPharma Group Company.

Dr. Cimler was SVP of Regulatory & Quality at Adaptive Biotechnologies where she developed the regulatory strategy for their NGS-based immunosequencing products and led regulatory interactions with pharma partners to allow use of NGS-based minimal residual disease tests in oncology drug trials and submissions. She was previously Head of Global Quality and Regulatory at Illumina where she led the regulatory strategy resulting in the first NGS platform receiving FDA marketing authorization. She held leadership positions in quality, regulatory, clinical and government affairs at Beckman Coulter, Abbott Molecular, Gen-Probe and C. R. Bard.

She serves on the Board of Directors of Monod Bio, Nanostics, and as a member of the Scientific Advisory Board of GRAIL.